Forget Lilly and Novo: Pfizer Is Planning a Wave of Phase 3 Obesity Trials
Everyone is talking about the GLP-1 battle between Eli Lilly and Novo Nordisk, but Pfizer wants in on the fight, too.
This Warren Buffett Dividend Stock Is the One I’d Buy With $1,000 in November
Warren Buffett's longtime investment offers a straightforward way to benefit from consumer spending.
Wall Street Is Ignoring Bristol Myers Squibb’s Cash Machine — and That’s an Opportunity for Income Investors
Bristol Myers Squibb has a 4% yield and a 55% payout ratio, which should greatly interest dividend lovers.
Did Apple Just Get a Boost From Democrats? Data Center Moratoriums Could Benefit the iPhone Maker
Competition for this key component in Apple devices could come down.
Think It’s Too Late to Buy Cloudflare Stock? Here’s the 1 Reason Why There’s Still Time
Cloudflare has nearly quadrupled in three years, but management says it has captured only about 1% of the market it's targeting.
Warren Buffett Warned Investors About This Number 27 Years Ago. It’s Never Been Higher. Should AI Investors Worry?
In 1999, Buffett said corporate profits couldn't stay much above 6% of the economy for long. They're now more than double that, and the AI spending boom is a big reason why.
MercadoLibre’s Profits Fall Again. What It Means for Investors
The Latin American e-commerce operator fell again on earnings. Is a recovery near?
